Patient-specific tumor neoantigen peptide–MHC class I complex (Neoantigen-MHC I complex)

Patient-specific tumor neoantigen peptide–MHC class I complexes are unique molecular structures formed when mutated proteins within a cancer cell are processed into short peptides and presented on the cell surface by Major Histocompatibility Complex (MHC) class I molecules (NIH, 2021). These complexes serve as highly specific "flags" that distinguish malignant cells from healthy tissue, as the neoantigens are derived from somatic mutations not present in the germline (Nature, 2014). The primary biological function of these complexes is to facilitate the recognition of tumor cells by the adaptive immune system, specifically by the T-cell receptors (TCRs) of CD8+ cytotoxic T cells (MDPI, 2021). In the context of cancer, the presence and density of these complexes are critical for the efficacy of immune checkpoint inhibitors and form the basis for personalized immunotherapy strategies (AACR, 2023). Therapeutic approaches targeting these complexes include personalized neoantigen vaccines (mRNA or peptide-based), which aim to prime the immune system to recognize these specific markers, and adoptive T-cell therapies (TCR-T), where T cells are engineered to target a patient's unique pMHC profile (NIH, 2022). Despite their potential, challenges such as tumor-mediated MHC downregulation and the technical difficulty of accurately predicting immunogenic neoantigens remain significant hurdles in clinical development (ResearchGate, 2023). Furthermore, the personalized nature of these targets requires sophisticated bioinformatics and rapid manufacturing processes to be clinically viable. Successful targeting of these complexes has the potential to provide durable, highly specific anti-tumor responses with minimal off-target effects on healthy tissues.

Other names

Tumor-specific neoantigen-MHC complexNeoepitope-HLA complexTSA-MHC complexNeoantigen-HLA-I complexpMHC-I complex

Induction of de novo T-cell responses and direct recognition of tumor cells by cytotoxic T-lymphocytes via T-cell receptor binding to the neoantigen-MHC complex.